Live price temporarily unavailable.
Minerva Neurosciences (NERV) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | $0 | $0 | $0 | $41.2M | $0 | $0 | $0 | $0 | — |
| Growth (year over year) | — | — | — | — | — | −100.0% | — | — | — | — |
| Operating income | −$30.2M | −$41.2M | −$51.7M | −$75.9M | $1.85M | −$45.4M | −$25.2M | −$23.1M | −$21.8M | −$15.1M |
| Operating margin | — | — | — | — | 4.5% | — | — | — | — | — |
| Net income | −$31.0M | −$31.5M | −$50.2M | −$72.2M | $1.94M | −$49.9M | −$32.1M | −$30.0M | $1.44M | −$293.4M |
| Net margin | — | — | — | — | 4.7% | — | — | — | — | — |
| EPS (diluted) | −$63.36 | −$53.12 | −$82.56 | −$14.80 | $0.40 | −$9.35 | −$6.01 | −$4.61 | $0.19 | −$34.67 |
| Balance sheet | ||||||||||
| Cash and equivalents | $83.0M | $26.1M | $50.2M | $21.4M | $25.4M | $60.8M | $36.1M | $40.9M | $21.4M | $82.3M |
| Total assets | $132.9M | $183.7M | $139.1M | $77.5M | $57.6M | $77.1M | $55.1M | $56.9M | $37.1M | $98.0M |
| Total liabilities | $27.0M | $52.1M | $48.9M | $49.7M | $4.96M | $69.1M | $75.1M | $85.4M | $62.8M | $233.8M |
| Shareholders' equity | $106.0M | $131.6M | $90.3M | $27.8M | $52.7M | $7.98M | −$20.0M | −$28.5M | −$25.7M | −$140.7M |
| Cash flow | ||||||||||
| Operating cash flow | −$25.7M | $3.09M | −$41.9M | −$43.4M | −$33.8M | −$24.6M | −$24.6M | −$14.8M | −$19.6M | −$13.5M |
| Capital expenditure | — | $52.4K | — | — | — | — | $16.3K | — | — | — |
| Free cash flow | — | $3.04M | — | — | — | — | −$24.7M | — | — | — |
| Share buybacks | — | $389 | — | — | — | — | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$4.37M | −$4.52M | −$3.90M | −$3.37M | −$2.84M | −$4.98M | −$16.7M | −$10.6M |
| Net income | $22.5M | −$4.27M | −$3.75M | −$3.26M | −$2.74M | −$283.7M | −$125.4M | $17.5M |
| EPS (diluted) | $2.97 | −$0.56 | −$0.50 | −$0.43 | −$0.36 | −$33.38 | −$2.86 | −$0.14 |
| Balance sheet | ||||||||
| Cash and equivalents | $26.5M | $21.4M | $17.3M | $15.2M | $12.3M | $82.3M | $32.7M | $24.7M |
| Total assets | $42.8M | $37.1M | $32.8M | $30.4M | $28.1M | $98.0M | $94.0M | $95.1M |
| Total liabilities | $64.5M | $62.8M | $61.9M | $62.5M | $62.7M | $233.8M | $343.1M | $296.6M |
| Shareholders' equity | −$21.7M | −$25.7M | −$29.1M | −$32.1M | −$34.6M | −$140.7M | −$254.0M | −$213.3M |
| Cash flow | ||||||||
| Operating cash flow | −$4.35M | −$5.17M | −$4.07M | −$2.04M | −$2.92M | −$4.48M | −$5.43M | −$13.3M |
From Minerva Neurosciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Minerva Neurosciences in our feed yet.